Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report

This case study explores the effectiveness of autologous cytokine-induced killer (CIK) cell-based immunotherapy in a 49-year-old male patient with inoperable stage IIIb cholangiocarcinoma, characterized by high levels of the sodium-dependent vitamin C transporter-2 (SVCT2) in immune cells. Despite a...

Full description

Saved in:
Bibliographic Details
Main Authors: Kangseok Kim, Hyunhye Wang, Jiewon Lee, Changhwan Yeom
Format: Article
Language:English
Published: Korean Society of Surgical Oncology 2024-12-01
Series:Korean Journal of Clinical Oncology
Subjects:
Online Access:http://www.kjco.org/upload/kjco-20-2-84.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850144737444495360
author Kangseok Kim
Hyunhye Wang
Jiewon Lee
Changhwan Yeom
author_facet Kangseok Kim
Hyunhye Wang
Jiewon Lee
Changhwan Yeom
author_sort Kangseok Kim
collection DOAJ
description This case study explores the effectiveness of autologous cytokine-induced killer (CIK) cell-based immunotherapy in a 49-year-old male patient with inoperable stage IIIb cholangiocarcinoma, characterized by high levels of the sodium-dependent vitamin C transporter-2 (SVCT2) in immune cells. Despite an initial lack of tumor reduction following chemotherapy, the patient showed a significant decrease in tumor markers and stabilization of the tumor after undergoing radiation and proton therapy. Subsequently, CIK cell therapy, combined with high-dose vitamin C, was administered 52 times over 6 years. The patient’s tumor size reduced, and no cancer activity was detected for 7 years and 10 months post-diagnosis, indicating a successful long-term outcome without recurrence. This study suggests that CIK cell therapy, particularly in patients with elevated SVCT2 levels, may offer a promising adjuvant treatment for cholangiocarcinoma and potentially other cancers. Further research is needed to validate SVCT2 as a biomarker for the effectiveness of CIK cell therapy.
format Article
id doaj-art-d9bb92fc7fa548d184c817c6b8b424e2
institution OA Journals
issn 1738-8082
2288-4084
language English
publishDate 2024-12-01
publisher Korean Society of Surgical Oncology
record_format Article
series Korean Journal of Clinical Oncology
spelling doaj-art-d9bb92fc7fa548d184c817c6b8b424e22025-08-20T02:28:16ZengKorean Society of Surgical OncologyKorean Journal of Clinical Oncology1738-80822288-40842024-12-01202848710.14216/kjco.24012427Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case reportKangseok Kim0Hyunhye Wang1Jiewon Lee2Changhwan Yeom3 Department of Surgery, Bangre Hospital, Incheon, Korea Department of Radiology, Bangre Hospital, Incheon, Korea Department of Family Medicine, Yeom Chang Hwan Hospital, Seoul, Korea Department of Family Medicine, Yeom Chang Hwan Hospital, Seoul, KoreaThis case study explores the effectiveness of autologous cytokine-induced killer (CIK) cell-based immunotherapy in a 49-year-old male patient with inoperable stage IIIb cholangiocarcinoma, characterized by high levels of the sodium-dependent vitamin C transporter-2 (SVCT2) in immune cells. Despite an initial lack of tumor reduction following chemotherapy, the patient showed a significant decrease in tumor markers and stabilization of the tumor after undergoing radiation and proton therapy. Subsequently, CIK cell therapy, combined with high-dose vitamin C, was administered 52 times over 6 years. The patient’s tumor size reduced, and no cancer activity was detected for 7 years and 10 months post-diagnosis, indicating a successful long-term outcome without recurrence. This study suggests that CIK cell therapy, particularly in patients with elevated SVCT2 levels, may offer a promising adjuvant treatment for cholangiocarcinoma and potentially other cancers. Further research is needed to validate SVCT2 as a biomarker for the effectiveness of CIK cell therapy.http://www.kjco.org/upload/kjco-20-2-84.pdfcell therapysodium-dependent vitamin c transporter-2ascorbic acidcholangiocarcinomacase reports
spellingShingle Kangseok Kim
Hyunhye Wang
Jiewon Lee
Changhwan Yeom
Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report
Korean Journal of Clinical Oncology
cell therapy
sodium-dependent vitamin c transporter-2
ascorbic acid
cholangiocarcinoma
case reports
title Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report
title_full Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report
title_fullStr Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report
title_full_unstemmed Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report
title_short Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report
title_sort long term tumor suppression in cholangiocarcinoma using cytokine induced killer cell therapy and high dose vitamin c a case report
topic cell therapy
sodium-dependent vitamin c transporter-2
ascorbic acid
cholangiocarcinoma
case reports
url http://www.kjco.org/upload/kjco-20-2-84.pdf
work_keys_str_mv AT kangseokkim longtermtumorsuppressionincholangiocarcinomausingcytokineinducedkillercelltherapyandhighdosevitamincacasereport
AT hyunhyewang longtermtumorsuppressionincholangiocarcinomausingcytokineinducedkillercelltherapyandhighdosevitamincacasereport
AT jiewonlee longtermtumorsuppressionincholangiocarcinomausingcytokineinducedkillercelltherapyandhighdosevitamincacasereport
AT changhwanyeom longtermtumorsuppressionincholangiocarcinomausingcytokineinducedkillercelltherapyandhighdosevitamincacasereport